Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OPK | 8-K | bullish | 7/10 | OPKO Health (OPK) has agreed to sell its BioReference clinical and anatomic pathology laboratory testing business, inclu | Oct 15, 2026 |
| EVFM | 8-K | neutral | 3/10 | Evofem Biosciences entered into a fifth amendment to its securities purchase agreement with Adjuvant, extending the matu | Oct 15, 2026 |
| ADTX | 8-K | bearish | 6/10 | Aditxt's wholly-owned subsidiary Ignite Proteomics mutually terminated its Business Combination Agreement with SPAC Copl | Oct 15, 2026 |
| MBIO | 8-K | bearish | 6/10 | Mustang Bio received Nasdaq notice that its stock failed to meet the $1.00 minimum bid price by the initial 180-day dead | Oct 15, 2026 |
| IAM | 424B4 | neutral | 6/10 | Iambic Therapeutics priced its IPO at $16.00 per share, offering 9,375,000 shares for total gross proceeds of $150.0 mil | Oct 15, 2026 |
| MGNX | PRESS-RELEASE | neutral | 3/10 | MacroGenics announced dosing of the first patient in a Phase 1 study of MGC030, a first-in-class ADC for advanced solid | Oct 15, 2026 |
| MYGN | PRESS-RELEASE | neutral | 1/10 | Myriad Genetics, Inc. announced it will report its Q3 2026 results on November 4, 2026. | Oct 15, 2026 |
| TCRT | SC 13D | neutral | 5/10 | Fairmount Funds Management LLC and affiliates have filed a Schedule 13D disclosing beneficial ownership of 19.99% of Ala | Oct 15, 2026 |
| ABBV | 8-K | neutral | 2/10 | AbbVie expanded its Board of Directors from 12 to 13 members and appointed Dr. John M. Carethers as a Class II independe | Oct 15, 2026 |
| IRD | PRESS-RELEASE | bullish | 6/10 | Opus Genetics presented interim clinical data at Retina in Rio 2026 for its two lead gene therapy programs. OPGx-BEST1 s | Oct 15, 2026 |
| AVXL | PRESS-RELEASE | neutral | 4/10 | Anavex received FDA clearance to proceed with its IND for blarcamesine (ANAVEX®2-73) in Fragile X syndrome, enabling a P | Oct 15, 2026 |
| RTSN | SC 13G | neutral | 3/10 | Laurence W. Lytton filed a Schedule 13G disclosing a 7.4% passive stake in Retension Pharmaceuticals, Inc., consisting o | Oct 15, 2026 |
| NBIX | SC 13G/A | neutral | 3/10 | JPMorgan Chase & Co. filed an amended Schedule 13G disclosing a 5.2% passive stake in Neurocrine Biosciences as of Septe | Oct 15, 2026 |
| SPRC | 6-K | bearish | 7/10 | SciSparc entered into an inducement letter with L.I.A Pure Capital Ltd. to convert $2,023,039.21 of outstanding converti | Oct 15, 2026 |
| TEVA | INST-CLUSTER | bearish | 4/10 | Three institutional investors exited or trimmed their positions in Teva during Q3 2026, with aggregate net selling of $1 | Oct 15, 2026 |
| NBIX | INST-CLUSTER | bullish | 4/10 | Three institutional asset managers accumulated $64.9M in NBIX during Q3 2026, led by Ninety One UK nearly doubling its s | Oct 15, 2026 |
| RGEN | INST-CLUSTER | mixed | 3/10 | Institutional activity in RGEN during Q3 2026 shows a mixed picture: Artemis Investment Management more than tripled its | Oct 15, 2026 |
| ANVS | SC 13G/A | neutral | 3/10 | Empery Asset Management filed an amended Schedule 13G disclosing beneficial ownership of 2,241,537 shares of Annovis Bio | Oct 15, 2026 |
| DYAI | SC 13G | neutral | 4/10 | Empery Asset Management, LP disclosed a new 8.35% passive stake in Dyadic International Inc. via a Schedule 13G filed Oc | Oct 15, 2026 |
| SPRC | 6-K | neutral | 3/10 | SciSparc announced a strategic shift toward Agentic AI-powered technologies, including cybersecurity and finance, buildi | Oct 15, 2026 |
| GSK | 6-K | neutral | 1/10 | GSK filed a routine 6-K reporting that three senior executives (SVP & Group General Counsel, President US, and Chief Dig | Oct 15, 2026 |
| VALN | 6-K | neutral | 2/10 | Valneva announced management participation in four upcoming healthcare conferences (Portzamparc/BNP Paribas, Guggenheim, | Oct 15, 2026 |
| CRBP | 8-K | neutral | 5/10 | Corbus Pharmaceuticals filed an 8-K furnishing an updated corporate presentation. The presentation highlights Phase 1/2 | Oct 15, 2026 |
| EPRX | 6-K | neutral | 5/10 | Eupraxia Pharmaceuticals announced it reached the enrollment target of 120 patients in the Phase 2b placebo-controlled p | Oct 15, 2026 |
| LLY | PRESS-RELEASE | neutral | 1/10 | Eli Lilly and Company announced it will host a conference call on October 29, 2026 to discuss its Q3 2026 results. | Oct 15, 2026 |
| SCNI | 6-K | bearish | 6/10 | Scinai Immunotherapeutics entered into a securities purchase agreement on October 13, 2026, to sell ADSs and pre-funded | Oct 15, 2026 |
| HELP | 6-K | neutral | 3/10 | Helus Pharma appointed Dr. Suresh Durgam, a former CMO of Intra-Cellular Therapies (acquired by J&J) to its Board of Dir | Oct 15, 2026 |
| BIAF | 8-K | neutral | 3/10 | bioAffinity Technologies filed an 8-K announcing a Learning Theater presentation at CHEST 2026 on October 21, 2026, high | Oct 15, 2026 |
| AAPG | 6-K | neutral | 1/10 | Ascentage Pharma's trustee purchased 200,000 existing shares (0.05% of issued shares) on-market for HK$5.78 million (~HK | Oct 15, 2026 |
| EDSA | 8-K | neutral | 4/10 | Edesa Biotech announced FDA clearance of its IND application for EB06, a monoclonal antibody targeting CXCL10, enabling | Oct 15, 2026 |